Wakamoto Pharmaceutical Co., Ltd. operates in the Pharmaceutical preparations sector.
In addition to historical fundamental analyses, the complete report available to purchase compares Wakamoto Pharmaceutical Co., Ltd. with three other
companies in this sector in Japan:
Koei Chemical Company, Limited
sales of 18.28 billion Japanese Yen [US$176.03 million]
Biofermin Pharmaceutical Company Limited
(9.67 billion Japanese Yen [US$93.09 million]
of which 62%
was New BioferminS), and
I'rom Group Co Ltd
(4.11 billion Japanese Yen [US$39.62 million]
of which 72%
was Smo Business).
Wakamoto Pharmaceutical Co., Ltd. reported sales of ¥11.18 billion (US$107.69 million)
March of 2016.
increase of 5.3%
versus 2015, when the company's sales were ¥10.62 billion.
This was the fourth straight year of sales growth at Wakamoto Pharmaceutical Co., Ltd..
Sales of Other Businesses saw an increase
that was more than double the company's growth rate: sales were up
45.3% in 2016, from
¥127.53 million to ¥185.25 million.
Wakamoto Pharmaceutical Co., Ltd. also saw significant increases in sales in
Drugs (up 26.0% to ¥2.94 billion)
Not all segments of Wakamoto Pharmaceutical Co., Ltd. experienced an increase in sales in 2016:
sales of Specified Sales Bussiness fell 6.9% to ¥2.31 billion.